Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Core Insights - The company experienced a transformational year, marking one of the most consequential periods in its history [1] - The acquisition of Avadel and the development of NT1 and NT2 data have positioned the company to enter the hypersomnolence market [1] - The commercial portfolio has performed well, with positive results from NT1 and NT2 data, and ongoing enrollment in the IH study [1] Company Developments - The company has made significant strides in the orexin receptor agonist class, indicating a strong market position [1] - The year has been characterized by key milestones that have enhanced the company's commercial capabilities [1] - The company is optimistic about its future prospects in a new commercial domain after years of preparation [1]